Tivic Health Has Partnered With Fletcher Spaght, To Accelerate Development Of Its Commercial Strategy For Non-Invasive Cervical Vagus Nerve Stimulation

Benzinga · Sep 17 21:07

Partners with leading growth strategy firm, Fletcher Spaght

Tivic Health Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght ("FSI"), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation ("ncVNS").

Polaris Market Research estimates the global vagus nerve stimulation market will grow from $8.59 billion in 2021 to $21.3 billion in 2030, a 10.6% CAGR over the forecast period. Additionally, IDTechEx has forecast peripheral nerve stimulation, the segment targeted by Tivic Health, will grow at 35% CAGR, one of the fastest growth segments in bioelectronic medicine.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Tivic Health Has Partnered With Fletcher Spaght, To Accelerate Development Of Its Commercial Strategy For Non-Invasive Cervical Vagus Nerve Stimulation

Risk Disclaimer